BTK-IN-19

Cat. No.: HY-152212

CAS No.: 1374240-01-3

Molecular Formula: $C_{21}H_{22}Cl_2N_6O$

Molecular Weight: 445.34

Target: Btk

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BTK-IN-19 (Compound 51) is a reversible BTK inhibitor with an IC_{50} of <0.001 μM[1].
IC_{50} & Target	IC50: <0.001 μM (BTK)[1]
In Vitro	BTK-IN-19 (Compound 51) (3 days) inhibits B-cell proliferation with an IC_{50} of 0.080 μM[1].BTK-IN-19 (Compound 51) (3 days) ▯▯ B ▯▯▯▯▯IC_{50} ▯ 0.080 μM[1]▯

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	B cells enriched from PBMC
Concentration:	
Incubation Time:	3 days
Result:	Inhibited B-cell proliferation with an IC_{50} of 0.080 μM.

In Vivo

BTK-IN-19 (Compound 51) (80 mg/kg; i.p.; once) inhibits CD69 in mice[1].

BTK-IN-19 (5 mg/kg; p.o.) demonstrates low-moderate in vivo clearance and modest oral exposure (%F > 34) in rats[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DBA/1 mice[1]
Dosage:	80 mg/kg
Administration:	IP, once
Result:	Demonstrated strong inhibition of CD69.

REFERENCES

[1]. Vandeveer GH, et al. Discovery of structural diverse reversible BTK inhibitors utilized to develop a novel in vivo CD69 and CD86 PK/PD mouse model. Bioorg Med Chem

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA